Retinal sensitivity after intravitreal injection of bevacizumab for the treatment of macular edema secondary to retinal vein occlusion

Retina

Volumn 29, Issue 6, 2009, Pages 757-767

  Yamaike, Noritatsu ^a   Tsujikawa, Akitaka ^a   Sakamoto, Atsushi ^a   Ota, Masafumi ^a   Kotera, Yuriko ^a   Miyamoto, Kazuaki ^a   Kita, Mihori ^a   Yoshimura, Nagahisa ^a  

^a KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; TRIAMCINOLONE ACETONIDE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DISEASE ASSOCIATION; FEMALE; FLUORESCENCE ANGIOGRAPHY; FUNCTIONAL ASSESSMENT; HUMAN; LASER COAGULATION; MALE; OPTICAL COHERENCE TOMOGRAPHY; PERIMETRY; PHOTORECEPTOR; PROSPECTIVE STUDY; RECURRENT DISEASE; RETINA FOVEA; RETINA MACULA EDEMA; RETINA MACULA LUTEA; RETINA VEIN OCCLUSION; TREATMENT DURATION; VISUAL ACUITY;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; FEMALE; FLUORESCEIN ANGIOGRAPHY; HUMANS; INJECTIONS; INTRAOCULAR PRESSURE; MACULAR EDEMA; MALE; MIDDLE AGED; OPHTHALMOSCOPY; PERIMETRY; PROSPECTIVE STUDIES; RETINA; RETINAL VEIN OCCLUSION; TOMOGRAPHY, OPTICAL COHERENCE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; VISUAL FIELDS; VITREOUS BODY;

EID: 67749095092     PISSN: 0275004X     EISSN: None     Source Type: Journal    
DOI: 10.1097/IAE.0b013e31819d4fbf     Document Type: Article

References (33)

1. The Branch Vein Occlusion Study Group. Argon laser photo-coagulation for macular edema in branch vein occlusion. Am J Ophthalmol 1984;98:271-282.
2. Glacet-Bernard A, Coscas G, Chabanel A, Zourdani A, Lelong F, Samama MM. Prognostic factors for retinal vein occlusion: prospective study of 175 cases. Ophthalmology 1996;103: 551-560.
3. Noma H, Funatsu H, Yamasaki M, et al. Aqueous humour levels of cytokines are correlated to vitreous levels and severity of macular oedema in branch retinal vein occlusion. Eye 2008;22:42-48.
4. Noma H, Minamoto A, Funatsu H, et al. Intravitreal levels of vascular endothelial growth factor and interleukin-6 are correlated with macular edema in branch retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol 2006;244:309-315.
5. Noma H, Funatsu H, Yamasaki M, et al. Pathogenesis of macular edema with branch retinal vein occlusion and intraocular levels of vascular endothelial growth factor and interleukin-6. Am J Ophthalmol 2005;140:256-261.
6. Natural history and clinical management of central retinal vein occlusion. The Central Vein Occlusion Study Group. Arch Ophthalmol 1997;115:486-491.
7. Evaluation of grid pattern photocoagulation for macular edema in central vein occlusion. The Central Vein Occlusion Study Group M Report. Ophthalmology 1995;102:1425-1433.
8. Bashshur ZF, Haddad ZA, Schakal A, Jaafar RF, Saab M, Noureddin BN. Intravitreal bevacizumab for treatment of neovascular age-related macular degeneration: a one-year prospective study. Am J Ophthalmol 2008;145:249-256.
9. Emerson MV, Lauer AK, Flaxel CJ, et al. Intravitreal bevaci-zumab (Avastin) treatment of neovascular age-related macular degeneration. Retina 2007;27:439-444.
10. Goff MJ, Johnson RN, McDonald HR, et al. Intravitreal bevacizumab for previously treated choroidal neovascularization from age-related macular degeneration. Retina 2007;27:432- 438.
11. Arevalo JF, Wu L, Sanchez JG, et al. Intravitreal bevacizumab (Avastin) for proliferative diabetic retinopathy: 6-months follow-up. Eye 2009;23:117-123.
12. Yazdani S, Hendi K, Pakravan M. Intravitreal bevacizumab (Avastin) injection for neovascular glaucoma. J Glaucoma 2007;16:437-439.
13. Costa RA, Jorge R, Calucci D, Melo LA Jr, Cardillo JA, Scott IU. Intravitreal bevacizumab (Avastin) for central and hemi-central retinal vein occlusions: IBeVO study. Retina 2007;27: 141-149.
14. Kriechbaum K, Michels S, Prager F, et al. Intravitreal avastin for macular oedema secondary to retinal vein occlusion: a prospective study. Br J Ophthalmol 2008;92:518-522.
15. Rabena MD, Pieramici DJ, Castellarin AA, Nasir MA, Avery RL. Intravitreal bevacizumab (Avastin) in the treatment of macular edema secondary to branch retinal vein occlusion. Retina 2007;27:419-425.
16. Hsu J, Kaiser RS, Sivalingam A, et al. Intravitreal bevacizumab (Avastin) in central retinal vein occlusion. Retina 2007; 27:1013-1019.
17. Priglinger SG, Wolf AH, Kreutzer TC, et al. Intravitreal bevacizumab injections for treatment of central retinal vein occlusion: six-month results of a prospective trial. Retina 2007;27: 1004-1012.
18. Ferrara DC, Koizumi H, Spaide RF. Early bevacizumab treatment of central retinal vein occlusion. Am J Ophthalmol 2007;144:864-871.
19. Stahl A, Agostini H, Hansen LL, Feltgen N. Bevacizumab in retinal vein occlusion-results of a prospective case series. Graefes Arch Clin Exp Ophthalmol 2007;245:1429-1436.
20. Iturralde D, Spaide RF, Meyerle CB, et al. Intravitreal bevacizumab (Avastin) treatment of macular edema in central retinal vein occlusion: a short-term study. Retina 2006;26:279-284.
21. Rohrschneider K, Springer C, Bültmann S, Völcker HE. Microperimetry - comparison between the micro perimeter 1 and scanning laser ophthalmoscope - fundus perimetry. Am J Ophthalmol 2005;139:125-134.
22. Springer C, Bültmann S, Völcker HE, Rohrschneider K. Fundus perimetry with the micro perimeter 1 in normal individuals: comparison with conventional threshold perimetry. Ophthalmology 2005;112:848-854.
23. Yamaike N, Kita M, Tsujikawa A, Miyamoto K, Yoshimura N. Perimetric sensitivity with the micro perimeter 1 and retinal thickness in patients with branch retinal vein occlusion. Am J Ophthalmol 2007;143:342-344.
24. Yodoi Y, Tsujikawa A, Kameda T, et al. Central retinal sensitivity measured with the micro perimeter 1 after photo-dynamic therapy for polypoidal choroidal vasculopathy. Am J Ophthalmol 2007;143:984 -994.
25. Murakami T, Tsujikawa A, Ohta M, et al. Photoreceptor status after resolved macular edema in branch retinal vein occlusion treated with tissue plasminogen activator. Am J Ophthalmol 2007;143:171-173.
26. Ota M, Tsujikawa A, Murakami T, et al. Association between integrity of foveal photoreceptor layer and visual acuity in branch retinal vein occlusion. Br J Ophthalmol 2007;91:1644-1649.
27. Ota M, Tsujikawa A, Murakami T, et al. Foveal photoreceptor layer in eyes with persistent cystoid macular edema associated with branch retinal vein occlusion. Am J Ophthalmol 2008; 145:273-280.
28. Yamaike N, Tsujikawa A, Ota M, et al. Three-dimensional imaging of cystoid macular edema in retinal vein occlusion. Ophthalmology 2008;115:355-362.
29. Rosenfeld PJ, Fung AE, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for macular edema from central retinal vein occlusion. Ophthalmic Surg Lasers Imaging 2005;36:336-339.
30. Costa RA, Calucci D, Skaf M, et al. Optical coherence tomography 3: automatic delineation of the outer neural retinal boundary and its influence on retinal thickness measurements. Invest Ophthalmol Vis Sci 2004;45:2399-2406.
31. Chen TC, Cense B, Miller JW, et al. Histologic correlation of in vivo optical coherence tomography images of the human retina. Am J Ophthalmol 2006;141:1165-1168.
32. Karacorlu M, Ozdemir H, Karacorlu SA. Resolution of serous macular detachment after intravitreal triamcinolone acetonide treatment of patients with branch retinal vein occlusion. Retina 2005;25:856-860.
33. Mandelcorn MS, Nrusimhadevara RK. Internal limiting membrane peeling for decompression of macular edema in retinal vein occlusion: a report of 14 cases. Retina 2004;24:348-355.